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Snakebite has become better recognized as a significant cause of death and disability in
Sub-Saharan Africa, but the health economic consequences to victims and health infrastruc-
tures serving them remain poorly understood. This information gap is important as it pro-
vides an evidence-base guiding national and international health policy decision making on
the most cost-effective interventions to better manage snakebite. Here, we assessed hospi-
tal-based data to estimate the health economic burden of snakebite in three regions of Bur-
kina Faso (Centre-Ouest, Hauts Bassins and Sud-Ouest).
Methodology
Primary data of snakebite victims admitted to regional and district health facilities (eg,
number of admissions, mortality, hospital bed days occupied) was collected in three
regions over 17 months in 2013/14. The health burden of snakebite was assessed using
Disability-Adjusted Life Years (DALYs) calculations based upon hospitalisation, mortality
and disability data from admitted patients amongst other inputs from secondary sources
(eg, populations, life-expectancy and age-weighting constants). An activity-based costing
approach to determine the direct cost of snake envenoming included unit costs of clinical
staff wages, antivenom, supportive care and equipment extracted from context-relevant
literature.
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Findings
The 10,165 snakebite victims admitted to hospital occupied 28,164 hospital bed days over
17 months. The annual rate of hospitalisation and mortality of admitted snakebite victims
was 173 and 1.39/100,000 population, respectively. The estimated annual (i) DALYs lost
was 2,153 (0.52/1,000) and (ii) cost to hospitals was USD 506,413 (USD 49/hospitalisation)
in these three regions of Burkina Faso. These costs appeared to be influenced by the num-
ber of patients receiving antivenom (10.90% in total) in each area (highest in Sud-Ouest)
and the type of health facility.
Conclusion
The economic burden of snake envenoming is primarily shouldered by the rural health cen-
tres closest to snakebite victims–facilities that are typically least well equipped or resourced
to manage this burden. Our study highlights the need for more research in other regions/
countries to demonstrate the burden of snakebite and the socioeconomic benefits of its
management. This evidence can guide the most cost-effective intervention from govern-
ment and development partners to meet the snakebite-management needs of rural commu-
nities and their health centres.
Author summary
The World Health Organisation has established a strategy to halve snakebite mortality
and morbidity by 2030. Achieving this ambitious target within a decade will require sub-
stantial investment from governments of countries most affected by snakebite. The bur-
den of snakebite however, is typically greatest in low-middle income countries with
already limited health budgets. Acquiring government support to prioritise snakebite over
other prevailing diseases will require evidence of the scale, causes, precise geographies and
health economic impacts of snakebite. While the snakebite research community has pro-
gressed the delivery of some of these evidence types, it has been weak at providing evi-
dence of the health economic burden of snakebite. Our hospital-based study identifies the
health (Disability-Adjusted Life Years) and financial burdens of snakebite to three districts
of Burkina Faso. We argue that funding of more health economic research, performed at
greater depth and that includes cost-effectiveness of snakebite treatment and other reme-
dial interventions is arguably the most effective tool to advocate for the policy support and
investment required of national and international health agencies to deliver WHO’s laud-
able 2030 target for snakebite.
Introduction
The World Health Organization recently launched a strategy to halve the global annual snake-
bite deaths (83,000–138,00) and disabilities (400,000) by 2030 [1,2]. Snakebite mortality and
morbidity burdens are the highest in tropical countries, particularly in Asia and Africa [3,4].
Snakebite can be considered a disease of rural poverty as demonstrated by the statistically sig-
nificant linear relationships between snakebite mortality rates and indices of poverty such as
the human development index and annual government expenditure on health [5]. Snakebite
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induced fatalities, morbidities and consequent loss of economic productivity add to the burden
of rural tropical populations that also suffer from high levels of other diseases of poverty,
which can be attributed to under-resourced, poorly accessible health services and insufficient
economic well-being.
Remedial intervention by health agencies and governments, especially in regions with com-
peting health priorities and limited resources, requires these agencies to have evidence of the
scale, causes, precise geographies and health economic impacts of snakebite [6,7]. In terms of
cause in sub-Saharan Africa, the recent Médecins Sans Frontières publication [8] identified
the need for urgent investment in the production of safe and effective antivenom for sub-Saha-
ran Africa, and the need for clinical trials. A meta-analysis of the literature on snakebite inci-
dence and mortality in sub-Saharan Africa [9] provided a significant advance in terms of scale
and geographies of snakebite: estimating an annual mortality of 7,331 rural snakebite victims
and between 5,908–14,614 amputations performed on snakebite survivors. Habib et al 2015
expressed this literature information, from 16 studies in West Africa, in terms of Disability
Adjusted Life Years (DALYs) and estimated that the snakebite burden across West Africa to
be 319,874 DALYs (95% Confidence Interval 245,375–402,654) [10]. The authors highlighted
that whilst the snakebite DALY estimate equates to that of other neglected diseases including
Buruli Ulcer, Echinococcosis, Leprosy, Trachoma, Yaws and Yellow Fever, the national,
regional and international investment in managing snakebite falls far short of that devoted to
these other diseases [10]. Evidence of the health economic impact of snakebite and its treat-
ment would help advocate for change to balance this disparity. Estimating the cost of manag-
ing snakebite envenoming at local hospital level is effective in highlighting gaps and informing
decision making by governments and other relevant stakeholders as to the most cost-effective
allocation of resources [11], evidence that is greatly lacking in sub-Saharan Africa.
This hospital-based study presents information on the health and economic burden of
snakebite in three regions of Burkina Faso. This analysis would ideally have been conducted
upon detailed epidemiological data collected from both community- and hospital-based sur-
veys of snakebite victims. However, these types of surveys are expensive and thus rarely per-
formed (particularly in a domain like snakebite that has been under-funded and under-
researched for decades) and were beyond our resources. Instead, to achieve this objective, we
teamed up with better-funded colleagues undertaking a Mass Drug Administration (MDA)
program for lymphatic filariasis in three regions in southern Burkina Faso to cost-efficiently
collect data from snakebite victims admitted to hospitals participating in this MDA program.
Methods
Ethics statement
The primary data used in this study did not include information on individual patients. Data
were limited to routine information that is available to technical staff of the Ministry of Health
for reports and publications that are authorised by the Ministry through the National
Neglected Diseases Control Program. A formal ethical approval was not required for this anal-
ysis of ministry of health data because ministry of health officials coordinating the National
NTD Control Programme collected the data for this study.
Study setting
This study was conducted in three regions (Centre-Ouest, Hauts Bassins and Sud-Ouest;
Fig 1) of Burkina Faso with a high burden of snakebite [12]. The total population of these three
states was 4,140,300 in 2014 [13]. More socio-economic and health systems indicators (e.g.
PLOS NEGLECTED TROPICAL DISEASES Health and economic burden of snakebite in southern Burkina Faso
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0009464 June 21, 2021 3 / 17
total population, poverty headcount, density of physicians and nurses per 1,000 population)
on Burkina Faso are provided in S1 Table.
Data collection
Both primary and secondary data were employed in this study. Primary data were gathered
from regional and district health centres in three regions of Burkina Faso (Centre-Ouest,
Sud-Ouest and Hauts Bassins) that participated in Mass Drug Administration programs
for Lymphatic Filariasis. Data collection took place over 17 months from June 2013 to
October 2014. Healthcare professionals were asked to prospectively complete data collec-
tion forms (S2 Table) concerning hospital admissions of snakebite victims and the services
provided to them using routine information collected for reports and publications of Min-
istry of Health. Cost information including the average wages of doctors and nurses and
the data on costs of necessary equipment and treatments were extracted from health facility
and existing literature [10,14]. In Burkina Faso health, services are organized into three
levels:
• Community health centers deliver basic preventive and curative primary healthcare [15]
• Regional/district hospitals represent the point of referral for primary healthcare centers and
are managed by a district health management team led by a medical officer [16]
• Teaching hospitals at the central/national level which provides more specialized services
Funding of these facilities is largely from central government [17]. We included two types
of health facilities in the three regions of Burkina Faso in this study namely:
• health centres (Centre de Santé et de Promotion Sociale (CSPS)/Centre Médical (CM)/Cen-
tre médical avec Antenne chirurgicale (CMA))
• regional or district hospitals (Centre Hospitalier Régional de Gaoua/CHR GAOUA and
Centre Hospitalier Regional de Koudougou/CHR KDG)
We have excluded data collected from the teaching hospital (Hospitalier Universitaire
Sanou Souro/CHU SS) because this was limited only to out-patient consultation.
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Health burden
We calculated the health burden of snakebite in terms of Disability Adjusted Life Years
(DALYs) using a WHO-provided template spreadsheet [18]. We analysed hospital data to
determine the annual number of admitted snakebite patients and weighted their severity using
a disability weighting of 1 for the death of a snakebite patient and 0.163 for a snakebite victim
suffering prolonged disability (equating to a loss of 83.7% of good health). In the absence of
accepted snakebite weightings, these DALY figures were adapted from ‘poisoning’ [19] as
deployed in previous snakebite DALY studies in Sri Lanka and Nigeria [10,20]. After weight-
ing, the annual number of life years lost due to premature mortality (YLL) and years lived with
disability (YLD) were determined, and the number of DALYs calculated as a sum of these:
DALYs = YLL+YLD
Following formulas were used to estimate YLL and YLD in this template,
YLL ¼ ðKCeraÞ=ðrþ bÞ2½e  ðrþbÞðLþaÞ½  ðrþ bÞðLþ aÞ   1�   e  ðrþbÞa½  ðrþ bÞa   1�� þ ð1
  KÞ=rð1   e  rLÞ ð1Þ
YLD ¼ DWfKCera=ðrþ bÞ2½e  ðrþbÞðLþaÞ½  ðrþ bÞðLþ aÞ   1�   e  ðrþbÞa½  ðrþ bÞa   1�� þ ð1   KÞ=rð1   e  rLÞg ð2Þ
Where, a = age of death/disability (years); r = discount rate (r = 3%); β = age weighting con-
stant (β = 0.04); K = age-weighting modulation constant (K = 1); C = adjustment constant for
age-weights (0.1658); L = standard life expectancy at age of death/disability (years);
DW = disability weight (DW = 0.163, metastasis stage).
We inputted populations, the incidence of snakebite envenoming and mortality, life expec-
tancy, and duration of illness by age group in the DALY estimation template. We also inserted
disability weight (0.163) for ‘poisoning’ from the global burden of disease study [19,20,21]–the
closest available metric to snake envenoming. Standard life expectancy by age for Burkina Faso
was obtained from the life table of Global Health Observatory data repository 2017 [22].
Economic burden
The direct economic burden of snakebite treatment to the health service providers of the three
Burkina Faso regions was calculated using an activity-based costing (ABC) approach. In this
approach, the services required to effectively manage the admitted snakebite patients were
identified and unit costs were estimated for each service [23,24] and included all the costs
incurred by the health facility for delivering the services to the patient [25]–see Table 1.
The average salary costs of the doctors and nurses was obtained from McCoy et al. (2008)
and approximations of treatment costs and consumables was described by Habib et al. (2015)
[10,14] from studies performed in Nigerian clinical settings that approximate to those in
Burkina Faso. Ideally, this information would have been collected by the data-entry form but
the unfunded nature of our study dictated a limited scale of work we could ask of our
collaborators.
The cost of snakebite treatment to the health infrastructure was calculated using the data
collected from the hospitals. The average daily cost for treating a snakebite patient was multi-
plied by the total number of hospital bed days reported from each health district. The cost per
hospital stay was multiplied by the total number of admissions within each health district. The
total cost of antivenom used by each health district was then determined by multiplying the
average cost of treating one patient with antivenom with the total number of patients receiving
antivenom in each health district. The sum of the estimated cost for each activity was used to
estimate the cost of snakebite to each health district in Burkina Faso throughout the 17 months
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study period. The figure was then adjusted to give the annual cost to each district and to each
regional health centre. Finally, an average cost per bed day was determined for each location
by dividing the total costs to each district throughout the 17 months study period by the total
number of bed days occupied by envenomed patients in that district. We used 2014 as the base
year for estimating cost and exacting the US$ value. One US$ was equivalent to 493.76 CFA
Franc in 2014 [14].
In order to test for the robustness of the two main outcomes (i.e. the total hospitalisation
cost and the hospitalization cost per patient); two univariate sensitivity analyses were per-
formed. Each input parameter was individually varied by 25%.
Results
Hospitalisation, death and disability of snakebite patients
The annual rate of snakebite patient hospital admissions was 173 per 100,000 population. The
highest admission rate was in Sud-Ouest (342.5 per 100,000) followed by Centre-Ouest (164.7
per 100,000) and lowest in Hauts Bassins (111.0 per 100,000). The annual death rate was 1.4
per 100,000 population for the three regions and highest (3.47/100,000) in the Sud-Ouest
region (Table 2).
Fig 2 illustrates the seasonal nature of snakebite in Burkina Faso, with hospital admissions
over the 17 months period peaking during the cooler and wetter months of May/June to
August/September and dropping during the driest months of December to January–typical for
West Africa. The rain season is the period of peak agricultural activity and thus the period
Table 1. Economic burden estimation of hospital services to snakebite patients.
Activity/Cost items Unit cost / per item cost Cost per patient (calculation and inflation adjustment Sources
1. Doctor Average yearly salary in 2014 = US$16,000
Daily Salary = US$43.40
Hourly Salary = US$4.34
60 minutes spent per hospitalised patient per day = $4.34 Health
facility
2. Nurse Average yearly Salary in 2014 = US$2,200
Daily Salary = US$6.02
Hourly Salary = US$0.60
1 hour spent with envenomed patient per day = $0.60 x 1 Health
facility






Included cost for 5ml syringe, small clean dry test-tube and
accessories (local sterilization with methylated spirit and
tourniquet which are used for the WBCT test
Cost per test = $0.31
10 tests in 7 days for a patient bitten by carpet viper (pCV = 85%)
and 1 test for a non-carpet viper bite (15%)
Average number of tests per patient = 0.85�10+0.15�1 = 8.65





1 vial = $78 (average cost per dose in 2014)
On average 2.53 doses of antivenom was used per patient = $
197.34
Gampini et. al estimated in 2014, 991 snakebite patients (4% of
24,779) received in total 2,509 doses of antivenom. Therefore on
average 2.53 doses (2,509/991) were used per patient.
[12]
6. Supportive care Analgesia (paracetamol, tramadol), blood transfusion,
intravenous rehydration fluids and surgery especially
debridement $18.75 per patient




Use of adrenaline injections, antihistamines (chlopheniramine
or promethazine injections) and or steroids (hydrocortisone
injection): $1.88 per patient
The proportion of carpet viper patient receive early adverse
reaction treatment = 0.19
The proportion of non-carpet viper patient receive early adverse
reaction treatment = 0.26
Proportion of snakebite victim receive early adverse reaction
treatment = 0.19�0.66+0.34�0.26 = 0.21
[27]
�20 Minute Whole Blood Clotting Test (WBCT)
https://doi.org/10.1371/journal.pntd.0009464.t001
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when subsistent famers are at greatest risk of snakebite [5]. On average 11% of the hospitalized
snakebite victims received antivenom.
Hospitalisation, death and disability of snakebite patients
Based upon the data available to us, snakebite accounts for the annual loss of 2,153 DALYs
(0.52 per 1,000) in these three regions of Burkina Faso (Table 3). The highest DALYs lost was
in the Sud-Ouest region followed by Hauts Bassins and Centre-Ouest. In total DALYs lost, the
share of Years Life Lost (60%) was higher than the share of Years Lived with Disability (40%).
A total of 10,165 snakebite patients were admitted to the collaborating hospitals and occu-
pied a total of 28,164 hospital bed days over the 17 months study period (Table 4). The average
length of stay in hospital was 2.6 days. A total of 1,109 patients received antivenom treatment
and 10 patients required surgery to manage venom-induced local tissue damage. The highest
number of hospitalisation services were delivered by CSPS/CM/CMA facilities. The average
length of stay was the highest in CHR GAOUA facilities (3.9 days) and followed by CHR KDG
(3.0 days) and CSPS/CM/CMA (2.5 days).
Table 2. Hospitalisation and death of snakebite victims over 17 months period between June 2013 and October 2014.
Region Centre-Ouest Hauts Bassins Sud-Ouest Total
Population� 1,468,966 1,898,361 772,973 4,140,300
Snakebite related hospitalization Number of patients hospitalized in 17 months 3,428 2,986 3,751 10,165
Annual rate of snakebite related hospitalization per 100,000 164.70 111.0 342.5 173.3
(95% CI) (158.30–171.40) (106.40–115.90) (329.70–355.90) (169.30–77.40)
Death due to snakebite Total death 17 months 20 24 38 82
Annual death rate per 100,000 0.96 0.89 3.47 1.39
(95% CI) (0.52–1.60) (0.52–1.43) (2.30–5.08) (1.06–1.81)
�Source: Institut national de la statistique et de la démographie 2014 [13]
https://doi.org/10.1371/journal.pntd.0009464.t002
Fig 2. Number of hospitalised snakebite patients in the three regions studied and the percentage of patients that did, and did not receive antivenom treatment.
https://doi.org/10.1371/journal.pntd.0009464.g002
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Antivenom treatment of snakebite victims
A total of 10.9% snakebite victims received antivenom treatment (Fig 3). More patients admit-
ted to hospitals in the Sud-Ouest region received such treatment (24.8%) than in the other
regions. Most (86.7%) of the treated patients received antivenom from CHR GAOUA hospitals.
The monthly mortality of hospitalised snakebite patients and the percentage of patients that
died after receiving antivenom treatment and without treatment is presented in Fig 4. Patients
not receiving antivenom exhibited a higher share of total deaths than antivenom treated
patients.
Economic burden
The estimated cost per bed day occupied by envenomed patients varied substantially between
locations and facility types (Table 5). The annual costs of hospital services to snakebite patients
was USD 506,413. The per-patient cost for hospitalisation was USD 49. This was the highest in
CHR GAOUA (USD 423) facility followed by CSPS/CM/CMA (USD 42). Sud-Ouest has a
higher per patient hospitalisation cost compared to the Hauts Bassins and Centre-Ouest
regions.
Fig 5 illustrates that of all the different hospitalisation costs, the highest was incurred by
antivenom use (30.5%) followed closely by supportive care (28.1%) and lower costs for hospital
beds (17.4%) and doctors’ visits (17.0%).
Table 3. Annual disease burden of snake envenoming in three regions of Burkina Faso (hospitalised patients only).
Region Years Lived with Disability (YLD) Years of Life Lost (YLL) Disability-adjusted life year (DALY) DALY per 1,000
Centre-Ouest 257 341 598 0.41
Hauts Bassins 221 409 630 0.33
Sud-Ouest 277 648 925 1.20
Total 755 1,398 2,153 0.52
DALY estimation parameters: Mean age at bite = 25–29 years; Remaining life expectancy = 43 years; [28] Disability weight = 0.163 [20]; Discount rate = 3%; For YLD
estimation, 3.2% patients were considered to suffer long term disability with an average of 13.4 years [29]
https://doi.org/10.1371/journal.pntd.0009464.t003





Total hospital days Length of stay Antivenom received Surgery (e.g. debridement or
amputation)Mean 95% CI
Region
Centre-Ouest 3,428 8,311 2.4 (2.3–2.6) 62 1
Hauts Bassins 2,986 6,610 2.0 (1.9–2.2) 118 2
Sud-Ouest 3,751 13,243 3.5 (3.3–3.8) 929 7
Total 10,165 28,164 2.6 (2.5–
2.7)
1,109 10
Types of health facility
CHR GAOUAa 399 1,571 3.9 (3.7–4.1) 346 7
CHR KDGb 153 471 3.0 (2.6–3.4) 43 -
CSPS/CM/CMAc 10198 26,122 2.5 (2.4–2.6) 720 3
aCHR GAOUA: Centre hospitalier régional de Gaoua (Regional/district hospital)
bCHR KDG: Centre hospitalier regional de Koudougou (Regional/district hospital)
cCSPS/CM/CMA: Centre de Santé et de Promotion Sociale/Centre Médical/Centre médical avec Antenne chirurgicale (Health centers)
https://doi.org/10.1371/journal.pntd.0009464.t004
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The results of the one-way sensitivity analysis are reported in tornado diagrams in Fig 6
below. Hospitalisation costs are sensitive to variations in cost of the antivenom test and in the
spending on supportive care. The cost of EAR per patient does not have a strong effect on the
outcome.
Discussion
The aforementioned 2019 WHO strategy to halve global snakebite mortality and morbidity by
2030 was mandated (WHA71.5) by the 2018 World Health Assembly [30] resolution on snake-
bite envenoming. This followed the 2017 decision by the WHO to add snakebite as one of its
priority Neglected Tropical Disease [31]. That WHA resolution was supported by 31 countries
and based upon admittedly weak incidence, mortality and morbidity figures [30]. No mention
was made of conventional health economic burden/impact statements, presumably because
these were unavailable for snakebite. Providing evidence of the health economic impact of
snakebite will assuredly help retain/strengthen support of these and other governments, and of
international health agencies and donors to guide their health intervention policies, which, in
turn, will help WHO achieve its snakebite strategy objectives.
Burkina Faso is a low-income Sahelian country with 40.1% of the population living below
the national poverty line, whose economy is dependent upon agriculture that employs 80% of
the working population [32]. The circumstances of these remote, predominantly subsistent-
farming, impoverished communities place them at particularly high snakebite risk [5–7] and
are precisely the type of communities that the WHO hope will benefit most from their new
strategy. In that context, the present study was undertaken to deliver new information on the
health and economic burden of snakebite to rural hospitals in three southern regions of Bur-
kina Faso.
Over the 17 months of this study in Centre-Ouest, Hauts Bassins and Sud-Ouest regions of
Bukina Faso, 10,165 snakebite patients were admitted to hospital (173.3/100,000; Table 2), par-
ticularly during the wetter May-September periods, where they consumed 28,164 hospital bed
Fig 3. Percentage of hospitalised snakebite patients that received antivenom treatment—by region (blue bars) and facility type (green bars).
https://doi.org/10.1371/journal.pntd.0009464.g003
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days. In terms of medical and geographic impact, the Sud-Ouest region shouldered the greatest
snakebite admission burden (342 admitted patients/100,000 population) and costs of anti-
venom administration (Fig 3). The majority (24.8%) of patients were admitted to CHR
GAOUA hospitals and it was these facilities that administered the vast majority (86.7%) of
antivenom treatments. This is because CHR hospitals manage more severe snakebite patients
who are referred from CSPS/CM/CMA facilities. Furthermore, the inhabitants of the south-
west (Gaoua) region are more rural than communities in the other two regions.
Fig 4. Number of hospitalised snakebite patient deaths and percentage deaths in patients who did, and did not receive antivenom treatment.
https://doi.org/10.1371/journal.pntd.0009464.g004
Table 5. Annual cost (USD) of hospital management of snakebite patients by region and types of health facility.
Region/types of facility Hospitalisation cost (USDa)
Doctor Nurse Hospital bed cost Diagnostic test Antivenom cost Supportive care EARMb cost Total cost Per patient cost
Region
Centre-Ouest 25,461 3,532 25,930 6,552 8,637 45,503 973 116,588 37
Hauts Bassins 20,250 2,809 20,623 6,787 16,437 47,131 1,008 115,045 34
Sud-Ouest 40,570 5,627 41,318 7,149 129,409 49,646 1,061 274,781 85
Types of facility
CHR KDGc 1,443 200 1,470 292 5,990 2,025 43 11,462 68
CHR GAOUAd 4,813 668 4,902 760 48,197 5,281 113 64,734 161
CSPS/CM/CMAe 80,026 11,100 81,501 19,436 100,295 134,974 2,886 430,217 41
Total 86,281 11,968 87,872 20,488 154,482 142,279 3,042 506,413 49
aUnited States Dollar
bEarly adverse reaction management
cCentre Hospitalier Regional de Koudougou
dCentre Hospitalier Régional de Gaoua; eCentre de Santé et de Promotion Sociale (CSPS)/Centre Médical (CM)/Centre médical avec Antenne chirurgicale (CMA)
https://doi.org/10.1371/journal.pntd.0009464.t005
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Of the total 10,165 admitted snakebite patients, 82 patients did not survive (0.8%; Table 2)
and 1,109 were treated with antivenom (10.9%). Antivenom administration was clearly associ-
ated with clinical benefit since the percentage of monthly deaths amongst treated patients was
substantially lower (ranging from 11–67%) than deaths of untreated patients (ranging from
33–100%; Fig 4). Our study was unable to determine whether the deaths of the untreated
patients was attributable to a lack of antivenom, to patients arriving with such severe patholo-
gies that antivenom administration was too late to prevent death, or to other causes. Notably
only 10 patients (0.09% of all admitted patients and 0.9% of treated patients) received debride-
ment or amputation surgery to correct venom-induced tissue damage–a figure that questions
the accuracy of the widely-accepted estimate that snakebite induced morbidity is 3–4 fold
higher than mortality rates. Despite extensive seasonal variation in monthly patient admission
(Fig 2) and mortality (Fig 4) rates, the rate of antivenom treatment was more constant (average
of 11% patients, Fig 2). The important 2016 Burkina Faso-wide, retrospective snakebite study
by Gampini et al examined centralised hospital records from 2010–2014 and determined a
national snakebite incidence rate of 136/100,000, a 1.2% mortality rate and also identified the
Sud-Ouest region as being at highest snakebite risk [12]. This study provided particularly valu-
able information on the annually changing availability and cost of the antivenoms in Burkina
Faso (FavAfrique; Sanofi, France and EchiTAb-Plus-ICP; Instituto Clodomiro Picado, Costa
Rica).
Fig 5. The percentage share of total hospitalisation cost by item.
https://doi.org/10.1371/journal.pntd.0009464.g005
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In terms of snakebite burden estimates, our analysis of the data from these 3 regions of Bur-
kina Faso yielded an annual estimated 2,153 DALYS/year, equating to 0.52/1,000 population.
The total estimated hospital cost of managing one snakebite patient was approximated at
USD 49. These DALY figures are nearly identical to the 0.5 DALYs/1,000 determined for
snakebite patients in Sri Lanka in 2013 [20], where cost of treatment (USD 128.8) was however
three-fold higher than in Burkina Faso. Two other sub-Saharan Africa studies also estimated
hospital costs of treating snakebite patients. In neighbouring NE Nigeria, where the Echis ocel-
latus saw-scaled viper also dominates snakebite incidence and mortality, treatment costs with
EchiTAb-Plus-ICP and the saw-scaled viper-specific antivenom, EchiTAbG (MicroPharm,
Wales) were estimated at USD 216.25 [10]. In KwaZulu Natal where the dominant biting spe-
cies, Naja mossambica spitting cobra causes extensive local tissue, hospital treatment costs
with the SAIMR polyvalent antivenom (South Africa Vaccine Producer, South Africa) were
identified as ranging between USD 1,156–2,827 [33]–substantially higher than in Burkina
Faso. In the context of other prevailing tropical diseases, it is instructive to note that the esti-
mated costs/patient of treating uncomplicated and complicated Malaria were USD 5.85 and
USD 30.26 respectively [34], presumably reflecting the difference between out- and in-patient
treatment costs and that hospital management of a snakebite patient is more expensive than a
complicated malaria patient.
We determined that the overall annual cost to hospitals of snakebite treatment in three
states of Burkina Faso was USD 506,413, with the burden being greatest in regional health cen-
tres (e.g. CSPS/CM/CMA). The variation in cost between locations and facility types appeared
Fig 6. One way sensitivity analysis on the total hospitalization cost and the hospitalization cost per patient.
https://doi.org/10.1371/journal.pntd.0009464.g006
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to be influenced by the number of patients receiving antivenom treatment in each area (e.g.
Sud-Ouest) and health facility (e.g. CHR GAOUA). Approximately 11% of hospital admissions
were treated with antivenom over the study period–this is more than double the Gampini et al
figure of 3.9% patients treated in the 4 years prior to our study [12]. This discrepancy might
reflect annually changing volumes of antivenom supplies, regional variation in antivenom
availability (we studied only 3 regions) and data/or collected from hospitals (ourselves) versus
from central records.
A landmark study examining the burden of snakebite across West Africa [10] determined
that hospital treatment of other more recognized NTDs (eg, trachoma, onchocerciais, lym-
phatic filariasis) received between USD 3.30 and 146.96 per DALY averted. In contrast, no
such funding existed then for snakebite. The authors emphasized that antivenom treatment of
snakebite has proved highly cost-effective and, with current costs per DALY averted ranging
between USD 56.88 to USD 99.61 (dependent on discounts made), represents a valuable allo-
cation of health resources [10]. A separate study assessed that lowering the price of antivenom
to USD 40/treatment would incur a USD 10 per DALY averted–a superior cost-effectiveness
compared to other NTDs previously described [35]. This is heavily supported by the sensitivity
analyses (Fig 6), which show that the cost of antivenom (as well as the cost of supportive care)
influence heavily the total cost of hospitalisation, which in turn influences the cost-effective-
ness of snakebite interventions.
In Burkina Faso, the total DALYs per 1,000 population was 63.31. Therefore, the share of
DALYs burden related to snakebite was 0.82% of total. According to The World Bank, the per
capita health expenditure in Burkina Faso was US$ 39.59 in 2014. Considering the total popu-
lation, the total health expenditure in the three selected regions (Centre-Ouest, Hauts Bassins
and Sud-Ouest) was US$ 164 million. Thus in the selected regions, the share of snakebite hos-
pitalization cost was 0.31% of the total health expenditure in 2014.
Health financing is a major challenge to the Burkina Faso Ministry of Health, with general
government expenditure on healthcare estimated at 12.8% of total government expenditure
[36]. The Burkina Faso government has provided an atypically high level of support for snake-
bite management: in 2010 snakebite was made a centrally notifiable event and, in 2015, the
price of antivenom was subsidised to USD 3.4—less than 5% of the commercial rate [12]. Such
laudable health policy changes would be expected to reduce the economic burden imposed on
health centres in Burkina Faso and thereby reduce the mortality and morbidity of snakebite
victims. If data was available that evidenced these medical and health economic outcomes
from this national investment in antivenom, it would likely encourage adoption of similar
health initiatives in other countries experiencing high snakebite hospital admissions.
Our study has provided an estimation of the health and economic burden of snakebite to
rural hospitals in Burkina Faso. Several limitations can be described which should be taken
into consideration when interpreting the results. Our poor funding base meant we were unable
to conduct more detailed surveys, including of communities, to examine the disease burden,
causes and costs. For example, we would have liked to determine, during the rain seasons, why
monthly antivenom supply rates did not increase with rising snakebite patient admissions and
deaths. Similarly, instead of relying upon estimates from other sources, we would have liked to
conduct more detailed, primary-data surveys to more precisely determine facility-wide costs
of snakebite management in each of the different tiers of the Burkina Faso health facilities and
understand which brands of antivenom were delivered and how these medicine-supply deci-
sions were made and their cost-effectiveness. Studies such as these provide very valuable infor-
mation but are expensive and were beyond our means. We excluded analysing data on the
total number of health facility consultations by snakebite victims (1.5m, Centre-Ouest; 1.8m,
Haut Bassins; 0.91m, Sud-Ouest). The total of 4.2m snakebite victims seeking hospital care
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seemed extraordinarily high and our data collection tool was ill equipped (because of funding
issues) to robustly investigate this figure–a loss of potentially very important data. Estimations
of cases and fatalities were extracted only from hospital-based collection systems and it is likely
that a large proportion of snakebite victims elected not to visit health facilities and so went
unreported–a 1994 study of rural Kenyan communities determined that 68% of snakebite vic-
tims did not seek hospital care [37]. Our data collection system relied on participation by busy
healthcare professionals and data were missing for several participating health facilities. We
excluded facilities with missing data when calculating averages, which may have affected the
results. Costs to hospitals should therefore only be considered as estimations. Data from only
three states of one country was examined therefore caution must be applied when extrapolat-
ing results nationally and to other countries in sub-Saharan Africa.
The most successful outcomes of snake envenomed patients are attributable to rapid medi-
cal attention and administration of antivenom. The reality however, is that antivenom is often
unavailable in remote hospitals closest to snakebite victims [5,6,12]. A 2011 study estimated
that the availability of antivenom in Africa is less than 2.5% of the need, because of prolonged
under-investment in antivenom manufacture, inconsistent antivenom demand and improper
usage [38]. When antivenoms are available, a great many, perhaps the majority, of snakebite
patients are unable to afford remarkably expensive antivenom treatments. A 2017 study con-
ducted in Kenya [39] reported that antivenom purchase costs to hospitals ranged from USD
48 to 315/vial—costs that should be at least tripled given the clinical need to administer 2–5
+ vials for an effective treatment. The antivenom dose is dictated by the snake species responsi-
ble, the amount of venom injected and the efficacy of the antivenom used [40]. Snakebite treat-
ment can require additional medical interventions, including assisted ventilation to prevent
respiratory collapse of paralysed snakebite victims, antibiotics to prevent infection of the bite
wound and a range of other drugs to manage antivenom-induced adverse effects and to pre-
vent renal damage and infarction [41,42]. These, together with the need for surgical interven-
tion to manage venom-induced tissue damage and necrosis, add to the complexity of
snakebite management and to the costs imposed upon under-resourced rural hospitals [5,9].
The cost of diagnostic test, supportive care and treatment of early adverse reactions were
extracted from a Nigerian study due to the unavailability of country-specific estimates [27].
The unit cost estimate can differ between these two countries, which will influence the total
cost estimate. However, this effect will not be very high as a major share of the total cost
(67.3%) were sourced from the Burkina Faso settings (Fig 5).
Healthcare in remote rural communities is poorly accessible and often inadequately
equipped to effectively manage snakebite. Regional and district level hospitals often lack the
necessary financial resources, clinical expertise, laboratory instruments and pharmaceutical
supplies to effectively deliver treatments. Reported shortcomings in medical training and text-
books on management of snakebite in Asian countries [43] will surely apply to other countries
with lesser financial resources. Given estimates that in some rural West African hospitals up to
10% of hospital beds can be occupied by snakebite patients, especially in the rain seasons [27],
it seems an imperative to equip these rural hospitals with the resources, staff and medicines
they need most–and especially so because of the economic importance of subsistence agricul-
ture in these communities. It needs to be acknowledged that health budgets of governments,
international health agencies and donors are finite and carefully prioritised. It is therefore
incumbent upon snakebite stakeholders to provide evidence from medical/health economic
research studies to guide how and where health agencies should allocate their resources for
maximum health and economic return.
Geopolitical solutions and funds to implement them are now sought to ensure that tropical
snakebite patients have access to effective healthcare. It is essential that adequately funded
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studies are conducted which help to present information to both tropical governments and
international health agencies that identify the scale, location and cost of the problem and help
identify the most cost- and medically-effective interventions. The present study meets that
remit to a limited (because of its inadequate funding) extent but nevertheless describes the cost
of snakebite management to rural African healthcare systems, and illustrates that snakebite
poses a substantial medical and economic strain on the healthcare infrastructure serving the
poorest rural communities. We hope this study describes the value of, and underscores the
need for more health economic research so that evidence gathers to help guide allocation of
resources that meets the clinical, medicinal and staffing needs of rural tropical health facilities
to effectively manage snakebite.
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